Exact Sciences Corporation has announced results from the first clinical study of its Oncodetect® molecular residual disease (MRD) test in early triple-negative breast cancer (TNBC). The data, presented at the San Antonio Breast Cancer Symposium (SABCS), show that the Oncodetect test strongly predicts distant recurrence following surgery in patients with early TNBC. The substudy, conducted in collaboration with the NSABP Foundation and the German Breast Group as part of the NSABP-B-59/GBG-96-GeparDouze trial, evaluated circulating tumor DNA (ctDNA) in blood samples collected before treatment and after surgery. Results demonstrated the test's ability to help identify patients at higher risk of recurrence, supporting its potential role in informing post-surgical treatment decisions. Exact Sciences intends to submit the data for peer-reviewed publication and to MolDx in support of Medicare coverage.